Integrated radiogenomic machine learning predicts neoadjuvant chemotherapy response in metastatic ovarian cancer
The IRON ensemble combined baseline clinical data, CA-125, ctDNA and CT radiomics from primary and metastatic lesions to estimate tumor-volume change during neoadjuvant chemotherapy for high-grade serous ovarian carcinoma. In an independent 42-patient Barts cohort, the integrated model achieved AUC 0.78 for RECIST 1.1 response classification versus 0.47 for a clinical-only model; radiomics-containing scores significantly correlated with volume change in internal holdout. The study also measured spatial heterogeneity, with omental lesions showing better response than pelvic/ovarian disease.
Technology: IRON ensemble combining elastic net, support-vector regression and random forest
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent 42-patient Barts cohort, the integrated model achieved AUC 0.78 for RECIST 1.1 response classification versus 0.47 for a clinical-only model; radiomics-containing scores significantly correlated with volume change in internal holdout. The model used historical Cambridge and Barts cohorts with baseline and post-treatment imaging, including an external retrospective test set.
- Still unknown: Model analysis of two prospective observational cohorts (training n=72, internal holdout n=20, external n=42), not a decision trial. External ctDNA unavailable and imputed to training means. Sample size limits generalizability; treatment benefit from model-guided decisions was not tested.
- AI role: Pretreatment clinical, blood and multi-lesion radiomic features predicted volumetric response to neoadjuvant chemotherapy. Held-out and external evaluation showed radiomics added predictive information beyond clinical variables.
Evidence sources: https://www.nature.com/articles/s41467-023-41820-7.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 77 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.